Introducing a Gatekeeping System for Amyloid Status Assessment in Mild Cognitive Impairment

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2022 Jul 13

PMID 35831715

Authors

E Doering

M C Hoenig

G N Bischof

K P Bohn

L M Ellingsen

T van Eimeren

A Drzezga

Affiliations

Soon will be listed here.

Abstract

Background: In patients with mild cognitive impairment (MCI), enhanced cerebral amyloid-β plaque burden is a high-risk factor to develop dementia with Alzheimer's disease (AD). Not all patients have immediate access to the assessment of amyloid status (A-status) via gold standard methods. It may therefore be of interest to find suitable biomarkers to preselect patients benefitting most from additional workup of the A-status. In this study, we propose a machine learning-based gatekeeping system for the prediction of A-status on the grounds of pre-existing information on APOE-genotype F-FDG PET, age, and sex.

Methods: Three hundred and forty-two MCI patients were used to train different machine learning classifiers to predict A-status majority classes among APOE-ε4 non-carriers (APOE4-nc; majority class: amyloid negative (Aβ-)) and carriers (APOE4-c; majority class: amyloid positive (Aβ +)) from F-FDG-PET, age, and sex. Classifiers were tested on two different datasets. Finally, frequencies of progression to dementia were compared between gold standard and predicted A-status.

Results: Aβ- in APOE4-nc and Aβ + in APOE4-c were predicted with a precision of 87% and a recall of 79% and 51%, respectively. Predicted A-status and gold standard A-status were at least equally indicative of risk of progression to dementia.

Conclusion: We developed an algorithm allowing approximation of A-status in MCI with good reliability using APOE-genotype, F-FDG PET, age, and sex information. The algorithm could enable better estimation of individual risk for developing AD based on existing biomarker information, and support efficient selection of patients who would benefit most from further etiological clarification. Further potential utility in clinical routine and clinical trials is discussed.

References

Verger A, Doyen M, Campion J, Guedj E . The pons as reference region for intensity normalization in semi-quantitative analysis of brain FDG PET: application to metabolic changes related to ageing in conventional and digital control databases. EJNMMI Res. 2021; 11(1):31. PMC: 7990981. DOI: 10.1186/s13550-021-00771-0. View

Rowe C, Ellis K, Rimajova M, Bourgeat P, Pike K, Jones G . Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010; 31(8):1275-83. DOI: 10.1016/j.neurobiolaging.2010.04.007. View

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

Jack Jr C, Albert M, Knopman D, McKhann G, Sperling R, Carrillo M . Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):257-62. PMC: 3096735. DOI: 10.1016/j.jalz.2011.03.004. View

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273-89. DOI: 10.1006/nimg.2001.0978. View

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P . Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005; 46(10):1625-32. View

Grimmer T, Wutz C, Drzezga A, Forster S, Forstl H, Ortner M . The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res. 2012; 10(1):82-5. View

Loewenstein D, Barker W, Chang J, Apicella A, Yoshii F, Kothari P . Predominant left hemisphere metabolic dysfunction in dementia. Arch Neurol. 1989; 46(2):146-52. DOI: 10.1001/archneur.1989.00520380046012. View

Hammes J, Bischof G, Bohn K, Onur O, Schneider A, Fliessbach K . One-Stop Shop: F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. J Nucl Med. 2020; 62(2):240-246. DOI: 10.2967/jnumed.120.244061. View

10.

Jagust W, Bandy D, Chen K, Foster N, Landau S, Mathis C . The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6(3):221-9. PMC: 2920531. DOI: 10.1016/j.jalz.2010.03.003. View

11.

Dukart J, Mueller K, Barthel H, Villringer A, Sabri O, Schroeter M . Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. Psychiatry Res. 2012; 212(3):230-6. DOI: 10.1016/j.pscychresns.2012.04.007. View

12.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L . Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256(3):240-6. DOI: 10.1111/j.1365-2796.2004.01380.x. View

13.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

14.

Duara R, Loewenstein D, Lizarraga G, Adjouadi M, Barker W, Greig-Custo M . Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity. Neuroimage Clin. 2019; 22:101800. PMC: 6447735. DOI: 10.1016/j.nicl.2019.101800. View

15.

Weise C, Chen K, Chen Y, Kuang X, Savage C, Reiman E . Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. Neuroimage Clin. 2018; 20:286-296. PMC: 6084012. DOI: 10.1016/j.nicl.2018.07.016. View

16.

Mattsson N, Groot C, Jansen W, Landau S, Villemagne V, Engelborghs S . Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimers Dement. 2018; 14(7):913-924. DOI: 10.1016/j.jalz.2018.02.009. View

17.

Kim J, Kim J, Jang H, Kim J, Kang S, Kim J . Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Sci Rep. 2021; 11(1):6954. PMC: 7997887. DOI: 10.1038/s41598-021-86114-4. View

18.

Kim S, Lee P, Oh K, Byun M, Yi D, Lee J . Deep learning-based amyloid PET positivity classification model in the Alzheimer's disease continuum by using 2-[F]FDG PET. EJNMMI Res. 2021; 11(1):56. PMC: 8192639. DOI: 10.1186/s13550-021-00798-3. View

19.

Mosconi L, Tsui W, Herholz K, Pupi A, Drzezga A, Lucignani G . Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008; 49(3):390-8. PMC: 3703818. DOI: 10.2967/jnumed.107.045385. View

20.

Sanabria-Diaz G, Martinez-Montes E, Melie-Garcia L . Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One. 2013; 8(7):e68860. PMC: 3720883. DOI: 10.1371/journal.pone.0068860. View